DOI:
10.1055/s-00034915
Onkologische Welt
LinksClose Window
References
Munshi NC. et al
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma: Initial KarMMa results“.
ASCO 2020 Abstract 8503
Access:
We do not assume any responsibility for the contents of the web pages of other providers.